Core Insights - Voyageur Pharmaceuticals Ltd. has signed a collaboration and funding agreement with Bayer, providing milestone-based funding support of up to USD 2.35 million to develop iodine for medical imaging contrast media [1][2][3] Company Developments - The agreement includes an initial payment of USD 350,000 upon execution, USD 1,000,000 upon commencement of a feasibility study for an iodine extraction plant in Oklahoma, and another USD 1,000,000 upon completion of the study [3] - Voyageur has acquired iodine intellectual property from Dr. Brian Mueller, positioning the company to be a key player in the global iodine supply chain [1] - The company aims to become the first domestic producer of iodine contrast media in the United States, enhancing the security of the North American healthcare supply chain [4][7] Project Details - Voyageur is working on feasibility studies for both the Bayer project and its own radiology drug production project, which includes producing barium contrast drugs from its Frances Creek project in British Columbia and iodine contrast media from the Anadarko basin in the USA [5][6] - Initial lab bench testing for the Bayer project has been completed, and the company plans to build a small transportable field unit to gather data for the feasibility study [6] Market Context - The global contrast media market was valued at USD 6.77 billion in 2024 and is projected to reach USD 13.86 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033 [8] - North America accounts for approximately 39.07% of the global iodine contrast media market, valued at USD 2.65 billion annually due to high imaging volumes [8] Strategic Vision - Voyageur aims to vertically integrate the barium and iodine contrast markets, controlling all primary input costs from sourcing raw materials to final production [10][13] - The company plans to transition into a high-margin domestic manufacturer of radiology drugs, ensuring product validation by regulatory agencies worldwide [11]
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Thenewswire·2026-02-23 13:20